Evercore began coverage on shares of Lycia Therapeutics (NASDAQ:LYCA – Get Free Report) in a report released on Tuesday, Briefing.com reports. The firm set an “outperform” rating and a $43.00 price target on the stock. Evercore‘s price objective indicates a potential upside of 50.30% from the stock’s previous close.
Several other research analysts have also commented on the stock. Wall Street Zen upgraded shares of Lycia Therapeutics to a “hold” rating in a report on Saturday, October 31st. Jefferies Financial Group assumed coverage on shares of Lycia Therapeutics in a research report on Tuesday. They set a “buy” rating and a $50.00 price target on the stock. Four analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $56.00.
Read Our Latest Analysis on Lycia Therapeutics
Lycia Therapeutics Price Performance
Lycia Therapeutics stock opened at $28.61 on Tuesday. Lycia Therapeutics has a 12 month low of $22.19 and a 12 month high of $36.49.
Insider Buying and Selling
In related news, major shareholder Venrock Healthcare Capital Par acquired 1,952,705 shares of Lycia Therapeutics stock in a transaction on Monday, October 26th. The shares were bought at an average price of $18.04 per share, for a total transaction of $35,226,798.20. Following the completion of the purchase, the insider directly owned 6,785,437 shares in the company, valued at $122,409,283.48. This trade represents a 40.41% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders bought 2,078,749 shares of company stock valued at $38,526,342 over the last 90 days.
About Lycia Therapeutics
Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.
Further Reading
- Five stocks we like better than Lycia Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
